Universal Technical Institute, Inc.
Universal Technical Institute, Inc. (UTI) Stock Competitors & Peer Comparison
See (UTI) competitors and their performances in Stock Market.
Peer Comparison Table: Education & Training Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| UTI | $31.54 | +0.03% | 1.7B | 30.01 | $1.05 | N/A |
| EDU | $46.68 | +2.55% | 7.6B | 20.30 | $2.30 | +1.24% |
| TAL | $10.00 | +1.83% | 6.1B | 71.43 | $0.14 | N/A |
| LRN | $129.94 | +0.56% | 5.7B | 20.36 | $6.38 | N/A |
| LOPE | $168.64 | -0.03% | 4.8B | 21.19 | $7.96 | N/A |
| ATGE | $115.12 | +0.72% | 4.1B | 19.48 | $5.91 | N/A |
| GHC | $918.76 | +1.60% | 4B | 6.51 | $141.16 | +0.78% |
| LAUR | $23.27 | +1.13% | 3.5B | 12.51 | $1.86 | N/A |
| COUR | $12.37 | +36.16% | 2B | -29.48 | -$0.42 | N/A |
| STRA | $78.40 | +0.99% | 1.9B | 16.75 | $4.68 | +3.04% |
Stock Comparison
UTI vs EDU Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, EDU has a market cap of 7.6B. Regarding current trading prices, UTI is priced at $31.54, while EDU trades at $46.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas EDU's P/E ratio is 20.30. In terms of profitability, UTI's ROE is +0.21%, compared to EDU's ROE of +0.10%. Regarding short-term risk, UTI is less volatile compared to EDU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check EDU's competition here
UTI vs TAL Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, TAL has a market cap of 6.1B. Regarding current trading prices, UTI is priced at $31.54, while TAL trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas TAL's P/E ratio is 71.43. In terms of profitability, UTI's ROE is +0.21%, compared to TAL's ROE of +0.02%. Regarding short-term risk, UTI is less volatile compared to TAL. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check TAL's competition here
UTI vs LRN Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, LRN has a market cap of 5.7B. Regarding current trading prices, UTI is priced at $31.54, while LRN trades at $129.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas LRN's P/E ratio is 20.36. In terms of profitability, UTI's ROE is +0.21%, compared to LRN's ROE of +0.23%. Regarding short-term risk, UTI is more volatile compared to LRN. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check LRN's competition here
UTI vs LOPE Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, LOPE has a market cap of 4.8B. Regarding current trading prices, UTI is priced at $31.54, while LOPE trades at $168.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas LOPE's P/E ratio is 21.19. In terms of profitability, UTI's ROE is +0.21%, compared to LOPE's ROE of +0.30%. Regarding short-term risk, UTI is more volatile compared to LOPE. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check LOPE's competition here
UTI vs ATGE Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, ATGE has a market cap of 4.1B. Regarding current trading prices, UTI is priced at $31.54, while ATGE trades at $115.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas ATGE's P/E ratio is 19.48. In terms of profitability, UTI's ROE is +0.21%, compared to ATGE's ROE of +0.17%. Regarding short-term risk, UTI is less volatile compared to ATGE. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check ATGE's competition here
UTI vs GHC Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, GHC has a market cap of 4B. Regarding current trading prices, UTI is priced at $31.54, while GHC trades at $918.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas GHC's P/E ratio is 6.51. In terms of profitability, UTI's ROE is +0.21%, compared to GHC's ROE of +0.15%. Regarding short-term risk, UTI is less volatile compared to GHC. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check GHC's competition here
UTI vs LAUR Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, LAUR has a market cap of 3.5B. Regarding current trading prices, UTI is priced at $31.54, while LAUR trades at $23.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas LAUR's P/E ratio is 12.51. In terms of profitability, UTI's ROE is +0.21%, compared to LAUR's ROE of +0.31%. Regarding short-term risk, UTI is more volatile compared to LAUR. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check LAUR's competition here
UTI vs COUR Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, COUR has a market cap of 2B. Regarding current trading prices, UTI is priced at $31.54, while COUR trades at $12.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas COUR's P/E ratio is -29.48. In terms of profitability, UTI's ROE is +0.21%, compared to COUR's ROE of -0.08%. Regarding short-term risk, UTI is less volatile compared to COUR. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check COUR's competition here
UTI vs STRA Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, STRA has a market cap of 1.9B. Regarding current trading prices, UTI is priced at $31.54, while STRA trades at $78.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas STRA's P/E ratio is 16.75. In terms of profitability, UTI's ROE is +0.21%, compared to STRA's ROE of +0.07%. Regarding short-term risk, UTI is less volatile compared to STRA. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check STRA's competition here
UTI vs PRDO Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, PRDO has a market cap of 1.9B. Regarding current trading prices, UTI is priced at $31.54, while PRDO trades at $28.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas PRDO's P/E ratio is 12.64. In terms of profitability, UTI's ROE is +0.21%, compared to PRDO's ROE of +0.16%. Regarding short-term risk, UTI is more volatile compared to PRDO. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check PRDO's competition here
UTI vs GOTU Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, GOTU has a market cap of 1.3B. Regarding current trading prices, UTI is priced at $31.54, while GOTU trades at $3.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas GOTU's P/E ratio is -7.32. In terms of profitability, UTI's ROE is +0.21%, compared to GOTU's ROE of -0.42%. Regarding short-term risk, UTI is less volatile compared to GOTU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check GOTU's competition here
UTI vs AFYA Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, AFYA has a market cap of 1.3B. Regarding current trading prices, UTI is priced at $31.54, while AFYA trades at $14.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas AFYA's P/E ratio is 10.80. In terms of profitability, UTI's ROE is +0.21%, compared to AFYA's ROE of +0.17%. Regarding short-term risk, UTI is less volatile compared to AFYA. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check AFYA's competition here
UTI vs KLC Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, KLC has a market cap of 1.2B. Regarding current trading prices, UTI is priced at $31.54, while KLC trades at $10.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas KLC's P/E ratio is -17.03. In terms of profitability, UTI's ROE is +0.21%, compared to KLC's ROE of -0.13%. Regarding short-term risk, UTI is less volatile compared to KLC. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check KLC's competition here
UTI vs UDMY Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, UDMY has a market cap of 1.1B. Regarding current trading prices, UTI is priced at $31.54, while UDMY trades at $7.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas UDMY's P/E ratio is -16.56. In terms of profitability, UTI's ROE is +0.21%, compared to UDMY's ROE of -0.32%. Regarding short-term risk, UTI is less volatile compared to UDMY. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check UDMY's competition here
UTI vs DAO Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, DAO has a market cap of 1B. Regarding current trading prices, UTI is priced at $31.54, while DAO trades at $8.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas DAO's P/E ratio is 51.29. In terms of profitability, UTI's ROE is +0.21%, compared to DAO's ROE of -0.07%. Regarding short-term risk, UTI is more volatile compared to DAO. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check DAO's competition here
UTI vs ARCE Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, ARCE has a market cap of 927.4M. Regarding current trading prices, UTI is priced at $31.54, while ARCE trades at $13.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas ARCE's P/E ratio is -73.58. In terms of profitability, UTI's ROE is +0.21%, compared to ARCE's ROE of +0.02%. Regarding short-term risk, UTI is more volatile compared to ARCE. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check ARCE's competition here
UTI vs REDU Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, REDU has a market cap of 730.3M. Regarding current trading prices, UTI is priced at $31.54, while REDU trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas REDU's P/E ratio is -23.04. In terms of profitability, UTI's ROE is +0.21%, compared to REDU's ROE of +0.15%. Regarding short-term risk, UTI is less volatile compared to REDU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check REDU's competition here
UTI vs LINC Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, LINC has a market cap of 721.9M. Regarding current trading prices, UTI is priced at $31.54, while LINC trades at $22.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas LINC's P/E ratio is 58.59. In terms of profitability, UTI's ROE is +0.21%, compared to LINC's ROE of +0.07%. Regarding short-term risk, UTI is less volatile compared to LINC. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check LINC's competition here
UTI vs APEI Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, APEI has a market cap of 547.1M. Regarding current trading prices, UTI is priced at $31.54, while APEI trades at $30.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas APEI's P/E ratio is 29.74. In terms of profitability, UTI's ROE is +0.21%, compared to APEI's ROE of +0.08%. Regarding short-term risk, UTI is less volatile compared to APEI. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check APEI's competition here
UTI vs QSG Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, QSG has a market cap of 492.7M. Regarding current trading prices, UTI is priced at $31.54, while QSG trades at $9.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas QSG's P/E ratio is 8.61. In terms of profitability, UTI's ROE is +0.21%, compared to QSG's ROE of +0.71%. Regarding short-term risk, UTI is less volatile compared to QSG. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check QSG's competition here
UTI vs VSTA Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, VSTA has a market cap of 331.2M. Regarding current trading prices, UTI is priced at $31.54, while VSTA trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas VSTA's P/E ratio is 4.05. In terms of profitability, UTI's ROE is +0.21%, compared to VSTA's ROE of +0.10%. Regarding short-term risk, UTI is less volatile compared to VSTA. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check VSTA's competition here
UTI vs VTRU Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, VTRU has a market cap of 304.2M. Regarding current trading prices, UTI is priced at $31.54, while VTRU trades at $9.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas VTRU's P/E ratio is 15.91. In terms of profitability, UTI's ROE is +0.21%, compared to VTRU's ROE of -0.01%. Regarding short-term risk, UTI is more volatile compared to VTRU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check VTRU's competition here
UTI vs CHGG Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, CHGG has a market cap of 168.9M. Regarding current trading prices, UTI is priced at $31.54, while CHGG trades at $1.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas CHGG's P/E ratio is -0.19. In terms of profitability, UTI's ROE is +0.21%, compared to CHGG's ROE of -3.67%. Regarding short-term risk, UTI is less volatile compared to CHGG. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check CHGG's competition here
UTI vs STG Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, STG has a market cap of 141.8M. Regarding current trading prices, UTI is priced at $31.54, while STG trades at $10.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas STG's P/E ratio is 3.36. In terms of profitability, UTI's ROE is +0.21%, compared to STG's ROE of +0.53%. Regarding short-term risk, UTI is less volatile compared to STG. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check STG's competition here
UTI vs LGCY Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, LGCY has a market cap of 139.2M. Regarding current trading prices, UTI is priced at $31.54, while LGCY trades at $11.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas LGCY's P/E ratio is 19.05. In terms of profitability, UTI's ROE is +0.21%, compared to LGCY's ROE of +1.07%. Regarding short-term risk, UTI is less volatile compared to LGCY. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check LGCY's competition here
UTI vs SKIL Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, SKIL has a market cap of 125.5M. Regarding current trading prices, UTI is priced at $31.54, while SKIL trades at $14.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas SKIL's P/E ratio is -0.91. In terms of profitability, UTI's ROE is +0.21%, compared to SKIL's ROE of -0.91%. Regarding short-term risk, UTI is less volatile compared to SKIL. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check SKIL's competition here
UTI vs GNS Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, GNS has a market cap of 98.3M. Regarding current trading prices, UTI is priced at $31.54, while GNS trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas GNS's P/E ratio is -1.09. In terms of profitability, UTI's ROE is +0.21%, compared to GNS's ROE of -0.41%. Regarding short-term risk, UTI is less volatile compared to GNS. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check GNS's competition here
UTI vs RYET Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, RYET has a market cap of 66.8M. Regarding current trading prices, UTI is priced at $31.54, while RYET trades at $1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas RYET's P/E ratio is -66.00. In terms of profitability, UTI's ROE is +0.21%, compared to RYET's ROE of -1.59%. Regarding short-term risk, UTI is less volatile compared to RYET. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check RYET's competition here
UTI vs ONE Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, ONE has a market cap of 51.3M. Regarding current trading prices, UTI is priced at $31.54, while ONE trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas ONE's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.21%, compared to ONE's ROE of -1.90%. Regarding short-term risk, UTI is less volatile compared to ONE. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check ONE's competition here
UTI vs KIDZ Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, KIDZ has a market cap of 35.4M. Regarding current trading prices, UTI is priced at $31.54, while KIDZ trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas KIDZ's P/E ratio is -102.50. In terms of profitability, UTI's ROE is +0.21%, compared to KIDZ's ROE of +0.30%. Regarding short-term risk, UTI is less volatile compared to KIDZ. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check KIDZ's competition here
UTI vs JZ Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, JZ has a market cap of 34.3M. Regarding current trading prices, UTI is priced at $31.54, while JZ trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas JZ's P/E ratio is -0.85. In terms of profitability, UTI's ROE is +0.21%, compared to JZ's ROE of -846.41%. Regarding short-term risk, UTI is less volatile compared to JZ. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check JZ's competition here
UTI vs IH Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, IH has a market cap of 31.2M. Regarding current trading prices, UTI is priced at $31.54, while IH trades at $2.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas IH's P/E ratio is 11.64. In terms of profitability, UTI's ROE is +0.21%, compared to IH's ROE of +0.11%. Regarding short-term risk, UTI is less volatile compared to IH. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check IH's competition here
UTI vs BTCT Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, BTCT has a market cap of 29M. Regarding current trading prices, UTI is priced at $31.54, while BTCT trades at $3.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas BTCT's P/E ratio is -4.62. In terms of profitability, UTI's ROE is +0.21%, compared to BTCT's ROE of -0.08%. Regarding short-term risk, UTI is less volatile compared to BTCT. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check BTCT's competition here
UTI vs AIU Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, AIU has a market cap of 18.8M. Regarding current trading prices, UTI is priced at $31.54, while AIU trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas AIU's P/E ratio is 0.51. In terms of profitability, UTI's ROE is +0.21%, compared to AIU's ROE of -1.90%. Regarding short-term risk, UTI is less volatile compared to AIU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check AIU's competition here
UTI vs YQ Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, YQ has a market cap of 18.4M. Regarding current trading prices, UTI is priced at $31.54, while YQ trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas YQ's P/E ratio is -0.73. In terms of profitability, UTI's ROE is +0.21%, compared to YQ's ROE of -0.42%. Regarding short-term risk, UTI is less volatile compared to YQ. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check YQ's competition here
UTI vs GEHI Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, GEHI has a market cap of 18.3M. Regarding current trading prices, UTI is priced at $31.54, while GEHI trades at $13.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas GEHI's P/E ratio is -0.24. In terms of profitability, UTI's ROE is +0.21%, compared to GEHI's ROE of -0.90%. Regarding short-term risk, UTI is less volatile compared to GEHI. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check GEHI's competition here
UTI vs AACG Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, AACG has a market cap of 15.9M. Regarding current trading prices, UTI is priced at $31.54, while AACG trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas AACG's P/E ratio is -7.19. In terms of profitability, UTI's ROE is +0.21%, compared to AACG's ROE of -0.43%. Regarding short-term risk, UTI is less volatile compared to AACG. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check AACG's competition here
UTI vs EDTK Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, EDTK has a market cap of 15.6M. Regarding current trading prices, UTI is priced at $31.54, while EDTK trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas EDTK's P/E ratio is -2.04. In terms of profitability, UTI's ROE is +0.21%, compared to EDTK's ROE of -0.36%. Regarding short-term risk, UTI is less volatile compared to EDTK. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check EDTK's competition here
UTI vs BEDU Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, BEDU has a market cap of 13.7M. Regarding current trading prices, UTI is priced at $31.54, while BEDU trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas BEDU's P/E ratio is -0.45. In terms of profitability, UTI's ROE is +0.21%, compared to BEDU's ROE of -1.61%. Regarding short-term risk, UTI is more volatile compared to BEDU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check BEDU's competition here
UTI vs VSA Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, VSA has a market cap of 12.6M. Regarding current trading prices, UTI is priced at $31.54, while VSA trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas VSA's P/E ratio is -0.17. In terms of profitability, UTI's ROE is +0.21%, compared to VSA's ROE of +0.36%. Regarding short-term risk, UTI is less volatile compared to VSA. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check VSA's competition here
UTI vs TEDU Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, TEDU has a market cap of 12.2M. Regarding current trading prices, UTI is priced at $31.54, while TEDU trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas TEDU's P/E ratio is -2.40. In terms of profitability, UTI's ROE is +0.21%, compared to TEDU's ROE of -0.05%. Regarding short-term risk, UTI is less volatile compared to TEDU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check TEDU's competition here
UTI vs VEDU Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, VEDU has a market cap of 9.3M. Regarding current trading prices, UTI is priced at $31.54, while VEDU trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas VEDU's P/E ratio is -1.91. In terms of profitability, UTI's ROE is +0.21%, compared to VEDU's ROE of -0.43%. Regarding short-term risk, UTI is less volatile compared to VEDU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check VEDU's competition here
UTI vs EEIQ Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, EEIQ has a market cap of 8.3M. Regarding current trading prices, UTI is priced at $31.54, while EEIQ trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas EEIQ's P/E ratio is -1.35. In terms of profitability, UTI's ROE is +0.21%, compared to EEIQ's ROE of -0.98%. Regarding short-term risk, UTI is less volatile compared to EEIQ. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check EEIQ's competition here
UTI vs GV Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, GV has a market cap of 6.7M. Regarding current trading prices, UTI is priced at $31.54, while GV trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas GV's P/E ratio is -1.14. In terms of profitability, UTI's ROE is +0.21%, compared to GV's ROE of -0.57%. Regarding short-term risk, UTI is less volatile compared to GV. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check GV's competition here
UTI vs WAFU Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, WAFU has a market cap of 6.3M. Regarding current trading prices, UTI is priced at $31.54, while WAFU trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas WAFU's P/E ratio is -7.94. In terms of profitability, UTI's ROE is +0.21%, compared to WAFU's ROE of -0.10%. Regarding short-term risk, UTI is more volatile compared to WAFU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check WAFU's competition here
UTI vs GSUN Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, GSUN has a market cap of 5.4M. Regarding current trading prices, UTI is priced at $31.54, while GSUN trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas GSUN's P/E ratio is -1.47. In terms of profitability, UTI's ROE is +0.21%, compared to GSUN's ROE of -2.21%. Regarding short-term risk, UTI is less volatile compared to GSUN. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check GSUN's competition here
UTI vs TCTM Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, TCTM has a market cap of 4.9M. Regarding current trading prices, UTI is priced at $31.54, while TCTM trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas TCTM's P/E ratio is -0.15. In terms of profitability, UTI's ROE is +0.21%, compared to TCTM's ROE of -0.01%. Regarding short-term risk, UTI is less volatile compared to TCTM. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check TCTM's competition here
UTI vs TWOU Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, TWOU has a market cap of 4.4M. Regarding current trading prices, UTI is priced at $31.54, while TWOU trades at $1.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas TWOU's P/E ratio is -0.01. In terms of profitability, UTI's ROE is +0.21%, compared to TWOU's ROE of -14.93%. Regarding short-term risk, UTI is less volatile compared to TWOU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check TWOU's competition here
UTI vs MYND Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, MYND has a market cap of 3.5M. Regarding current trading prices, UTI is priced at $31.54, while MYND trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas MYND's P/E ratio is -0.33. In terms of profitability, UTI's ROE is +0.21%, compared to MYND's ROE of -1.26%. Regarding short-term risk, UTI is less volatile compared to MYND. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check MYND's competition here
UTI vs CLEU Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, CLEU has a market cap of 3.5M. Regarding current trading prices, UTI is priced at $31.54, while CLEU trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas CLEU's P/E ratio is -0.00. In terms of profitability, UTI's ROE is +0.21%, compared to CLEU's ROE of -0.13%. Regarding short-term risk, UTI is less volatile compared to CLEU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check CLEU's competition here
UTI vs FEDU Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, FEDU has a market cap of 3.3M. Regarding current trading prices, UTI is priced at $31.54, while FEDU trades at $14.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas FEDU's P/E ratio is 245.67. In terms of profitability, UTI's ROE is +0.21%, compared to FEDU's ROE of +0.00%. Regarding short-term risk, UTI is less volatile compared to FEDU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check FEDU's competition here
UTI vs METX Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, METX has a market cap of 3.1M. Regarding current trading prices, UTI is priced at $31.54, while METX trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas METX's P/E ratio is 0.79. In terms of profitability, UTI's ROE is +0.21%, compared to METX's ROE of -0.08%. Regarding short-term risk, UTI is less volatile compared to METX. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check METX's competition here
UTI vs COE Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, COE has a market cap of 2.9M. Regarding current trading prices, UTI is priced at $31.54, while COE trades at $28.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas COE's P/E ratio is -49.42. In terms of profitability, UTI's ROE is +0.21%, compared to COE's ROE of +0.32%. Regarding short-term risk, UTI is less volatile compared to COE. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check COE's competition here
UTI vs KIDZW Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, KIDZW has a market cap of 2.4M. Regarding current trading prices, UTI is priced at $31.54, while KIDZW trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas KIDZW's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.21%, compared to KIDZW's ROE of +0.19%. Regarding short-term risk, UTI is less volatile compared to KIDZW. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check KIDZW's competition here
UTI vs ASPU Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, ASPU has a market cap of 1.6M. Regarding current trading prices, UTI is priced at $31.54, while ASPU trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas ASPU's P/E ratio is -0.47. In terms of profitability, UTI's ROE is +0.21%, compared to ASPU's ROE of -0.42%. Regarding short-term risk, UTI is less volatile compared to ASPU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check ASPU's competition here
UTI vs RYB Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, RYB has a market cap of 1M. Regarding current trading prices, UTI is priced at $31.54, while RYB trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas RYB's P/E ratio is 1.87. In terms of profitability, UTI's ROE is +0.21%, compared to RYB's ROE of +0.05%. Regarding short-term risk, UTI is less volatile compared to RYB. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check RYB's competition here
UTI vs LXEH Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, LXEH has a market cap of 960.3K. Regarding current trading prices, UTI is priced at $31.54, while LXEH trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas LXEH's P/E ratio is -0.46. In terms of profitability, UTI's ROE is +0.21%, compared to LXEH's ROE of -0.05%. Regarding short-term risk, UTI is less volatile compared to LXEH. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check LXEH's competition here
UTI vs AMBO Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, AMBO has a market cap of 369.9K. Regarding current trading prices, UTI is priced at $31.54, while AMBO trades at $2.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas AMBO's P/E ratio is 23.55. In terms of profitability, UTI's ROE is +0.21%, compared to AMBO's ROE of +0.38%. Regarding short-term risk, UTI is less volatile compared to AMBO. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check AMBO's competition here
UTI vs BTCTW Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, BTCTW has a market cap of 13.6K. Regarding current trading prices, UTI is priced at $31.54, while BTCTW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas BTCTW's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.21%, compared to BTCTW's ROE of -0.08%. Regarding short-term risk, UTI is less volatile compared to BTCTW. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check BTCTW's competition here
UTI vs HLG Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, HLG has a market cap of 0. Regarding current trading prices, UTI is priced at $31.54, while HLG trades at $14.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas HLG's P/E ratio is 5.29. In terms of profitability, UTI's ROE is +0.21%, compared to HLG's ROE of +0.11%. Regarding short-term risk, UTI is more volatile compared to HLG. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check HLG's competition here
UTI vs NEW Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, NEW has a market cap of 0. Regarding current trading prices, UTI is priced at $31.54, while NEW trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas NEW's P/E ratio is -0.55. In terms of profitability, UTI's ROE is +0.21%, compared to NEW's ROE of -0.09%. Regarding short-term risk, UTI is less volatile compared to NEW. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check NEW's competition here
UTI vs ZME Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, ZME has a market cap of 0. Regarding current trading prices, UTI is priced at $31.54, while ZME trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas ZME's P/E ratio is -0.00. In terms of profitability, UTI's ROE is +0.21%, compared to ZME's ROE of -1.88%. Regarding short-term risk, UTI is less volatile compared to ZME. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check ZME's competition here
UTI vs HMHC Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, HMHC has a market cap of 0. Regarding current trading prices, UTI is priced at $31.54, while HMHC trades at $21.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas HMHC's P/E ratio is 12.54. In terms of profitability, UTI's ROE is +0.21%, compared to HMHC's ROE of +0.01%. Regarding short-term risk, UTI is more volatile compared to HMHC. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check HMHC's competition here
UTI vs ZVO Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, ZVO has a market cap of 0. Regarding current trading prices, UTI is priced at $31.54, while ZVO trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas ZVO's P/E ratio is -0.08. In terms of profitability, UTI's ROE is +0.21%, compared to ZVO's ROE of -1.07%. Regarding short-term risk, UTI is less volatile compared to ZVO. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check ZVO's competition here
UTI vs GPX Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, GPX has a market cap of 0. Regarding current trading prices, UTI is priced at $31.54, while GPX trades at $20.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas GPX's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.21%, compared to GPX's ROE of +0.03%. Regarding short-term risk, UTI is more volatile compared to GPX. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check GPX's competition here
UTI vs FHS Comparison July 2025
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, FHS has a market cap of 0. Regarding current trading prices, UTI is priced at $31.54, while FHS trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 30.01, whereas FHS's P/E ratio is 0.55. In terms of profitability, UTI's ROE is +0.21%, compared to FHS's ROE of N/A. Regarding short-term risk, UTI is less volatile compared to FHS. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check FHS's competition here